Last reviewed · How we verify
OMP-54F28, Nab-Paclitaxel and Gemcitabine
OMP-54F28, a novel Wnt pathway inhibitor, is being evaluated in combination with nab-paclitaxel and gemcitabine for the treatment of advanced pancreatic cancer. The Phase 1 trial has been completed, showing promising preliminary results. No FDA approval yet.
At a glance
| Generic name | OMP-54F28, Nab-Paclitaxel and Gemcitabine |
|---|---|
| Sponsor | OncoMed Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: